Home › Sequella Acquires Exclusive Worldwide Rights To Pfizer's Sutezolid, Currently In Clinical Development For Tuberculosis
 

Keywords :   


Sequella Acquires Exclusive Worldwide Rights To Pfizer's Sutezolid, Currently In Clinical Development For Tuberculosis

2013-07-17 04:00:00| drugdiscoveryonline Home Page

Sequella, a clinical-stage pharmaceutical company commercializing novel antibiotics to treat life-threatening infectious diseases, recently announced that it has licensed Pfizer Inc’s exclusive worldwide rights to develop and commercialize sutezolid, a Phase 2 oxazolidinone antibiotic currently in development for the treatment of tuberculosis (TB)

Tags: rights development worldwide exclusive

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.10Atlantic Tropical Weather Outlook
06.10Tropical Storm Milton Graphics
06.10Tropical Storm Milton Public Advisory Number 3A
06.10Summary for Tropical Storm Milton (AT4/AL142024)
06.10Eastern North Pacific Tropical Weather Outlook
06.10Hurricane Leslie Graphics
06.10Hurricane Kirk Graphics
06.10Hurricane Leslie Forecast Discussion Number 15
More »